Week 51: December 15 – December 21, 2013

ILLINOIS DEPARTMENT OF PUBLIC HEALTH



# Illinois Influenza Surveillance Report

Week 51: Week Ending Saturday, December 21, 2013

Division of Infectious Diseases Communicable Disease Section 12/27/2013

## Week 51: December 15 – December 21, 2013

## **Contents**

Summary	3
CDC FluView	4
ILINet Provider Surveillance	5
ILI Visits by Age Group	6
Influenza Intensive Care Unit (ICU) Admissions and Deaths	7
Influenza Related ICU Admissions by Age Group, 2012-2014	8
Laboratory Surveillance	9
Influenza Outbreaks Reported in Long-Term Facilities (LTC) and Nursing Homes (NH)	10
Viral Resistance	10
Weekly Viral Subtype	11
IDPH Infectious Diseases Regional Map/Provider Map	12
Resources	13

#### **Summary**

- For this reporting week, the proportion of outpatient visits for influenza-like illness (ILI)<sup>1</sup> was **1.94%**, which is **above** the regional baseline of **1.60%**.
- Based on CDC criteria, Illinois influenza activity is classified as Regional (see CDC FluView Section) for this reporting week.
- For this reporting week there were 267 influenza specimens tested by WHO/NREVSS collaborating Illinois laboratories (which includes all Illinois Department of Public Health Laboratories). Fifty-one specimens tested positive for Influenza.
- **Eighteen** influenza-associated Intensive Care Unit (ICU) admissions³ were reported for this reporting week.
- No influenza-associated pediatric deaths were reported for this reporting week.
- For this reporting week, no influenza outbreaks were reported in a long-term care facility.

#### **Novel Influenza A**

#### H3N2v/H10N8

No new cases have been reported

#### H7N9

- No new cases of H7N9 have been reported
- According to the European Centre for Disease Prevention and Control, there have been a total of 147 laboratory-confirmed cases and 47 deaths to date.
- Click Here for a full epidemiological update including maps and diagrams.

<sup>&</sup>lt;sup>1</sup> ILI "Influenza like Illness" is defined as fever ≥ 100°F and cough and/or sore throat.

<sup>&</sup>lt;sup>2</sup> FRI surveillance is ongoing at 8 U.S. military basic training centers, representing all service branches. FRI Rate Status is classified into one of 3 categories:


At or below expected value

<sup>2.</sup> Moderately elevated

Substantially elevated

<sup>&</sup>lt;sup>3</sup> For the purpose of diagnosis, influenza can be diagnosed by using the following test: reverse transcription polymerase chain reaction RT-PCR], viral culture, Immunofluorescence [Direct Fluorescent Antibody (IFA) or Indirect Fluorescent Antibody (IFA) Staining], Enzyme Immuno Assay (EIA) or any rapid diagnostic test. Sensitivities of rapid diagnostic tests are approximately 50-70% when compared with viral culture or reverse transcription polymerase chain reaction (RT-PCR), and specificities of rapid diagnostic tests for influenza are approximately 90-95%. False-positive (and true-negative) results are more likely to occur when disease prevalence in the community is low, which is generally at the beginning and end of the influenza seasons. False-negative (and true-positive) results are more likely to occur when disease prevalence is high in the community, which is typically at the height of the influenza season.

#### **CDC FluView**



<sup>\*</sup> This map indicates geographic spread & does not measure the severity of influenza activity

**No activity:** No laboratory confirmed cases of influenza and no reported increase in cases of influenza like illness (ILI).

**Sporadic:** Small numbers of laboratory confirmed influenza cases or a single laboratory confirmed influenza in a single region of the state.


**Local:** Outbreaks of influenza or increases in ILI and recent laboratory confirmed influenza in a single region of the state.

**Regional:** Outbreaks of influenza or increases in ILI and recent laboratory confirmed influenza in at least two but less than half the regions of the state.

**Widespread:** Outbreaks of influenza or increases in ILI cases and recent laboratory confirmed influenza in at least half the regions in the state.


#### **ILINet Provider Surveillance**

#### Influenza Like Illness Outpatient Surveillance 2012-2014



#### **ILI Visits by Age Group**

# 2012-2014 INFLUENZA SEASON PROPORTION OF ILI OFFICE VISITS BY AGE GROUP




# **Influenza Intensive Care Unit (ICU) Admissions and Deaths**

There were 18 influenza related ICU admissions and 0 deaths for this reporting week.

Year	Week No	Admissions	Deaths <sup>4</sup>
2013	40	2	0
2013	41	1	0
2013	42	1	0
2013	43	3	0
2013	44	1	0
2013	45	5	1
2013	46	2	0
2013	47	2	1
2013	48	6	1
2013	49	3	0
2013	50	17	0
2013	51	18	0
-	risional) for Season	61	3

#### Influenza Related ICU Admissions by Age Group, 2012-2014



#### **Laboratory Surveillance**

• For this reporting week there were **267** influenza specimens tested by WHO/NREVSS collaborating Illinois laboratories (which includes all Illinois Department of Public Health Laboratories). **Fifty-one** specimens tested positive for Influenza.

For more information about circulating viruses visit:

St Louis Children's Hospital Weekly Virus/Microbiology Update:
http://slchlabtestquide.bjc.org/Default.aspx?url=63e0653d-fe31-466f-9228-d4de90fa7424

Year	Week	A (H1)	2009(A) H1N1	A (H3)	A (Unable to subtype)	A (Sub typing not performed)	В	Total # Tested	Total # Positive	% Positive
2013	45	0	1	0	0	2	0	173	3	2.0%
2013	46	0	2	0	0	0	1	185	3	2.0%
2013	47	0	2	0	0	1	0	132	3	2.0%
2013	48	0	2	0	0	5	1	162	8	5.0%
2013	49	0	7	1	0	4	0	194	12	6.0%
2013	50	0	19	0	0	5	5	208	29	14.0%
2013	51	0	21	0	0	30	0	267	51	19.0%
То	tals	0	55	2	0	47	7	1,709	111	6.50 %

#### Influenza Outbreaks Reported in Long-Term Facilities (LTC) and Nursing Homes (NH)

There were **no** outbreaks reported in long-term care facilities for this reporting week.

Region	2013-2014 Influenza Season -Number of outbreaks (%)
Rockford (1)	0(0)
Peoria (2),	0(0)
Edwardsville (4),	0(0)
Marion (5),	0(0)
Champaign (6),	0(0)
West Chicago (7)	0(0)
Chicago/Cook (8)	0(0)
Total	0(0)

#### **Viral Resistance:**

Antiviral Resistance: Testing of 2009 H1N1, influenza A (H3N2), and influenza B virus isolates for resistance to neuraminidase inhibitors (oseltamivir and zanamivir) is performed at CDC using a functional assay. Additional 2009 H1N1 and influenza A (H3N2) clinical samples are tested for mutations of the virus known to confer oseltamivir resistance. The data summarized below combine the results of both testing methods. These samples are routinely obtained for surveillance purposes rather than for diagnostic testing of patients suspected to be infected with antiviral-resistant virus.

High levels of resistance to the adamantanes (amantadine and rimantadine) persist among 2009 influenza A (H1N1) and A (H3N2) viruses (the adamantanes are not effective against influenza B viruses). As a result, data from adamantine resistance testing are not presented below.

Neuraminidase Inhibitor Resistance Testing Results on Samples Collected Since October 1, 2013


	Ose	ltamivir	Zanamivir		
	Virus Samples tested (n)	Resistant Viruses, Number (%)	Virus Samples tested (n)	Resistant Viruses, Number (%)	
Influenza A (H3N2)	56	0 (0.0)	56	0 (0.0)	
Influenza B	12	0 (0.0)	12	0 (0.0)	
2009 H1N1	768*	10 (1.3)	476	0 (0.0)	

<sup>\*</sup>Includes specimens tested in national surveillance and additional specimens tested at public health laboratories in 10 states (AZ, CO, FL, HI, MD, MI, NY, TX, WA, and WI) who share testing results with CDC.

The majority of currently circulating influenza viruses are susceptible to the neuraminidase inhibitor antiviral medications oseltamivir and zanamivir; however, rare sporadic cases of oseltamivir-resistant 2009 H1N1 and A (H3N2) viruses have been detected worldwide. Antiviral treatment with oseltamivir or zanamivir is recommended as early as possible for patients with confirmed or suspected influenza who have severe, complicated, or progressive illness; who require hospitalization; or who are at greater risk for serious influenza-related complications. Additional information on recommendations for treatment and chemoprophylaxis of influenza virus infection with antiviral agents is available at <a href="http://www.cdc.gov/flu/antivirals/index.htm">http://www.cdc.gov/flu/antivirals/index.htm</a>.

## **Weekly Viral Subtype**

Influenza Isolates from Illinois Reported by WHO/NREVSS Collaborating Laboratories, 2013-2014 Influenza Season



#### **IDPH Infectious Diseases Regional Map** Jo Daviess Stephenson McHenry Lake ß Carroll Ogle Whiteside Lee Kendall Bureau Rock Island Henry La Salle Grundy Mercer Putnam Kankakee Stark Marshall Knox Livingston Warren Woodford Peoria 2 Iroquois Tazewell McLean McDonough Fulton Champaign Mason Vermilion De Witt Schuyler Logan 8 Menard Adams Brown Macon Douglas Morgan Edgar Moultrie Scott Christian Shelby Greene Clark Macoupin Montgomery Cumberland Jersey Effingham Crawford Jasper Fayette Madison Bond 1 - Rockford Region Lawrence Clay Richland Marion Clinton 2 - Peoria Region St. Clair Wayne 4 - Edwardsville Region Washington Jefferson Monroe 5 - Marion Region White Perry Hamilton Randolph **Indicates ILI Sentinel** Franklin 6 - Champaign Region **Provider Participant** Williamson Jackson Saline Gallatin, 5

Hardin

Union

Johnson

Pope

7 – West Chicago Region

8 - Chicago/Cook Co Region

#### Resources

- Centers for Disease Control and Prevention Influenza Website: <a href="http://www.cdc.gov/flu/">http://www.cdc.gov/flu/</a>
- Immunization Action Coalition Website: http://immunize.org/
- IDPH Seasonal Influenza Website: http://www.idph.state.il.us/flu/surveillance.htm
- St Louis Children's Hospital Weekly Virus/Microbiology Update: http://slchlabtestguide.bjc.org/Default.aspx?url=63e0653d-fe31-466f-9228-d4de90fa7424
- CDC Avian Influenza A (H7N9): <a href="http://www.cdc.gov/flu/avianflu/h7n9-virus.htm">http://www.cdc.gov/flu/avianflu/h7n9-virus.htm</a>.
- European Centre for Disease Prevention and Control <a href="http://www.ecdc.europa.eu/en/press/news/">http://www.ecdc.europa.eu/en/press/news/</a> layouts/forms/News DispForm.aspx?List=8db7286c-fe2d-476c-9133-

<u>18ff4cb1b568&ID=930&RootFolder=%2Fen%2Fpress%2Fnews%2FLists%2FNews&Source=http%3A%2F%2F</u> www.ecdc.europa.eu%2Fen%2Fpages%2Fhome.aspx&Web=86661a14-